FQ Restriction for the Prevention of CDI

Completed

Conditions studied: Clostridium Difficile, Clostridium Difficile Infection, C Difficile Colitis

In brief

This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs). The investigators will model a successful FQ PPA strategy in several Wisconsin ICUs and compare whether the intervention has improved outcomes in reducing CDIs. An additional goal of the study is to evaluate environmental and work system factors using systems engineering models in order to determine the most successful way to implement these new strategies.

Key facts

Study ID
NCT03848689
Run by
University of Wisconsin, Madison
People needed
5871
Starts
2019-05-01
Expected to finish
2024-05-31
Last updated by the study team
2025-01-31

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.